New CAR T strategy highly effective against small cell lung cancer in preclinical study

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

A University of Oklahoma physician-researcher recently received $2.9 million in funding from NCI to study whether RedHill Biopharma’s drug opaganib, given after CAR T-cell therapy, can help the immune cells fight cancer more effectively.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

An investigational CAR T therapy can lead to deep and durable responses in people with relapsed/refractory multiple myeloma, according to a phase I clinical trial led by investigators at Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center.

October 23, 2026

Vol.52 No.39

Podcast

As USPSTF falters, the idea that “screening is always good” is gaining traction

With the pope’s lung cancer diagnosis jumpstarting conversations about lung cancer screening and the constant buzz surrounding multi-cancer detection tests, evidence-based evaluation of screening tests is more important than ever.

October 21, 2026

News Analysis

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Pope Leo XIV has been diagnosed with lung adenocarcinoma. According to missives from the Holy See, the pope underwent surgery to remove the lower lobe of his right lung Oct. 13.

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Chronic exposure to cigarette smoke may reprogram different populations of lung stem cells, which maintain and repair lung tissue, in ways that make them vulnerable to specific cancer-causing gene alterations and ultimately helps determine the type of lung cancer that develops.

October 09, 2026

Vol.52 No.37

Clinical Roundup

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.

October 02, 2026

Vol.52 No.36

New CAR T strategy highly effective against small cell lung cancer in preclinical study

YOU MAY BE INTERESTED IN

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

As USPSTF falters, the idea that “screening is always good” is gaining traction

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Renew today!

Subscriber content

Never miss an issue!

Login

New CAR T strategy highly effective against small cell lung cancer in preclinical study

YOU MAY BE INTERESTED IN

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

As USPSTF falters, the idea that “screening is always good” is gaining traction

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Never miss an issue!

Login

The lung cancer diagnosis of Pope Leo—believed to be a never-smoker—sparks conversations around screening
“Even when the patient is the pope, advances in cancer treatment don’t arrive by divine intervention.”